Vanguard Group
STLN

Vanguard Group’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Vanguard Group’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$16.9M Buy
4,748,635
+203,390
+4% +$754K ﹤0.01% 2695
2025
Q3 		$15.9M Buy
4,545,245
+264,358
+6% +$906K ﹤0.01% 2738
2025
Q2 		$8.78M Buy
4,280,887
+2,530,173
+145% +$6.33M ﹤0.01% 2974
2025
Q1 		$2M Sell
1,750,714
-3,672
-0.2% -$2.84K ﹤0.01% 3490
2024
Q4 		$542K Sell
1,754,386
-29,068
-2% -$7.54K ﹤0.01% 3926
2024
Q3 		$583K Hold
1,783,454
– – ﹤0.01% 3931
2024
Q2 		$820K Hold
1,783,454
– – ﹤0.01% 3856
2024
Q1 		$2.82M Buy
1,783,454
+6,061
+0.3% +$11.5K ﹤0.01% 3485
2023
Q4 		$3.63M Buy
1,777,393
+19,359
+1% +$33.6K ﹤0.01% 3402
2023
Q3 		$2.46M Sell
1,758,034
-4,916
-0.3% -$5.09K ﹤0.01% 3514
2023
Q2 		$970K Sell
1,762,950
-180,593
-9% -$95.6K ﹤0.01% 3909
2023
Q1 		$1.32M Buy
1,943,543
+10,937
+0.6% +$14K ﹤0.01% 3829
2022
Q4 		$3.19M Buy
1,932,606
+72,364
+4% +$203K ﹤0.01% 3492
2022
Q3 		$8.61M Buy
1,860,242
+284,807
+18% +$1.67M ﹤0.01% 3026
2022
Q2 		$7.97M Buy
1,575,435
+737,114
+88% +$5.37M ﹤0.01% 3111
2022
Q1 		$5.98M Buy
838,321
+395,977
+90% +$2.67M ﹤0.01% 3445
2021
Q4 		$4.31M Buy
+442,344
New +$3.93M ﹤0.01% 3692

Other funds holding STLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Vanguard Group's STLN Position: Q4 2025 in Review

Vanguard Group increased its Starling Oncology Institute, Inc. Common Stock (STLN) stake by 4.5% in Q4 2025, buying an estimated $754K and bringing the position to 4,748,635 shares worth $16.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2695.

Vanguard Group first reported a position in STLN in Q4 2021 and has held it in 17 quarters since. 117 funds tracked by Wall St. Rank hold STLN as of Q4 2025.

  • Vanguard Group held 4,748,635 shares of Starling Oncology Institute, Inc. Common Stock worth $16.9M as of Q4 2025.
  • Vanguard Group bought 203,390 Starling Oncology Institute, Inc. Common Stock shares in Q4 2025, an estimated $754K.
  • Starling Oncology Institute, Inc. Common Stock made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2695 holding.
  • Vanguard Group first reported a position in Starling Oncology Institute, Inc. Common Stock in Q4 2021 and has held it in 17 quarters since.
  • 117 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.